



Ref: JSTL/BOD/BSE/2025-26/Aug25

Date: August 14, 2025

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

Sub: Outcome of Board Meeting held on 14.08.2025

With reference to the subject cited, this is to inform the exchange that the Board of Directors of Jeevan Scientific Technology Limited at its meeting held on Thursday, 14.08.2025 at 04:30 p.m. at the registered office of the Company, inter alia approved the following items of business:

1. Un-Audited Financial Results (Standalone and Consolidated) for the Quarter ended 30.06.2025. **(Attached)**
2. Limited Review Report (Standalone and Consolidated) for the Quarter ended 30.06.2025. **(Attached)**
3. Re-Appointment of Mr. Krishna Kishore Kuchipudi as Managing Director of the Company for a period of 3 years w.e.f. 01.04.2026, subject to approval of the members. (Brief profile is enclosed as **Annexure A**).
4. Appointment of Mr. Gollapinni Mallikarjuna (DIN- 11189083) as additional Director (Non- Executive Independent category) of the Company w.e.f.14.08.2025, subject to approval of the members (Brief profile is enclosed as **Annexure A**).
5. Re-appointment of Mr. Diwakar Atluri, Director of the Company, Retire by rotation, subject to approval of the members in the ensuing Annual General Meeting (AGM). (Brief Profile attached as **Annexure B**)
6. Re-appointment of Mr. Jeevan Krishna Kuchipudi, Director of the Company, Retire by rotation, subject to approval of the members in the ensuing Annual General Meeting (AGM). (Brief Profile attached as **Annexure B**).
7. Resignation of Mr. Thammareddy Ravi (DIN 01274099) as Director of the Company (Details are attached as **Annexure c**)



8. Granting of 3,00,000 (Three Lakhs Only) Stock options to the eligible employees of Company and the Subsidiary Company (Nayas Laboratories Private Limited) pursuant to JSTL ESOP Scheme 2016 as recommended by Nomination and Remuneration Committee, the Board of Directors, subject to necessary approvals in this regard. (Refer **Annexure – D**)
9. Notice of the Annual General Meeting (AGM) and Directors Report for the financial year 2024-25.
10. Annual General Meeting for the FY 2024-25 is scheduled to be held on Saturday, 27th September, 2025 at 10:00 a.m. through video conference or other audio-visual means.

The meeting concluded at 05:30 P.M.

This is for the information and records of the Exchange, please.

Thanking You.

Yours faithfully,

For Jeevan Scientific Technology Limited

Kodati Krishna Sainadh
Company Secretary & Compliance Officer

Encl as above



Annexure A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

Particulars	Mr. Krishna Kishore Kuchipudi	Mr. Gollapinni Mallikarjuna
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Krishna Kishore Kuchipudi as Managing Director of the Company	Appointment of Mr. Gollapinni Mallikarjuna as additional Director (Non-Executive Independent category) of the Company w.e.f.14.08.2025
Date of appointment & Terms of appointment	Re-appointed w.e.f. 01-April-2026 at a remuneration of Rs. 9,00,000/- (Rupees Nine Lakhs Only) per month for a period of 3 years, subject to approval of shareholders.	Appointment of Mr. Gollapinni Mallikarjuna as additional Director (Non-Executive Independent category) of the Company w.e.f.14.08.2025, subject to approval of shareholders.
Brief Profile	Mr. K. Krishna Kishore is the Promoter and Managing Director of the Company. He is a Postgraduate from Andhra University. He is the Chief architect of Jeevan Mitra Chit Fund Private Limited, Hyderabad. Under his aegis and stewardship as Vice-Chairman and Managing Director, the Company has grown impressively in size and has built its brand in India and abroad. He has played multiple roles throughout his career including but not limited	Mr. Gollapinni Mallikarjuna is former Principal Commissioner of Income Tax with over three decades of distinguished service in the Indian Revenue Service (IRS), Ministry of Finance, Government of India. Proven expertise in taxation, corporate dispute resolution, investigation, policy formulation, administration, and governance. Recognized for leadership in managing large teams, overseeing complex tax



	to mentor, advisor, investor, entrepreneur, board member helping visionary leaders realize their dreams.	operations, and coordinating with government and corporate stakeholders for sustainable economic development. Currently leveraging strategic leadership skills as CEO of SNR eDatas and serving as an advisor/consultant to leading infrastructure and biotechnology companies. Known for excellence in revenue collection, corporate taxation, dispute resolution, and national policy execution.
Disclosure of relationships between directors (in case of appointment of a director)	Except Mr. Jeevan Krishna Kuchipudi, Non-Executive Director and Ms. Snigdha Mothukuri, Executive Director being his relatives, none of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise.	None of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise.
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no NSE/CML/2018/24 dated June 20, 2018	Mr. K. Krishna Kishore is not de-barred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.	Mr. Gollapinni Mallikarjuna is not de-barred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.



Annexure B

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with of SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

Particulars	Mr. Divakar Atluri	Mr. Jeevan Krishna Kuchipudi
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Divakar Atluri, Director of the Company, Retire by rotation.	Re-appointment of Mr. Jeevan Krishna Kuchipudi, Director of the Company, Retire by rotation.
Date of appointment & Terms of appointment	Date of Appointment: w.e.f. ensuing AGM, subject to the approval of shareholders Terms of Appointment: Reappointment of Mr. Divakar Atluri, Director of the Company, Retire by rotation, subject to the approval of members in the ensuing AGM.	Date of Appointment: w.e.f. ensuing AGM, subject to the approval of shareholders Terms of Appointment: Re-appointment of Mr. Jeevan Krishna Kuchipudi, Director of the Company, Retire by rotation, subject to the approval of members in the ensuing AGM.
Brief Profile	Mr. Divakar Atluri, Chartered Accountant, Commerce Graduate is a fellow member of the Institute of Chartered Accountants of India (ICAI) having experience of 39 years in the field of Auditing, Taxation and Other Laws, Fund Management, Corporate Laws and Others.	Mr. Jeevan Krishna Kuchipudi is a passionate leader and an enthusiastic honors business graduate with diverse global experience, exceptionally in IT, Operations and Finance. He pursued undergraduate program for engineering in Computer Science from VNR Vignana Jyothi Institute of Engineering



		& Technology and Masters in Business Administration (MBA) in Finance from San Diego State University.
Disclosure of relationships between directors (in case of appointment of a director)	Mr. Divakar Atluri is not related to any of the Directors or Key Managerial Personnel or Promoters of the Company.	Mr. Jeevan Krishna Kuchipudi is not related to any of the Directors or Key Managerial Personnel of the Company except being related to Mr. Krishna Kishore Kuchipudi, Managing Director and Mrs. Snigdha Mothukuri, Executive Director.
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no NSE/CML/2018/24 dated June 20, 2018	Mr. Divakar Atluri is not de-barred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.	Mr. Jeevan Krishna Kuchipudi is not de-barred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.



Annexure C

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with of SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

Particulars	Mr. Thammareddy Ravi (DIN 01274099)
Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation of Mr. Thammareddy Ravi (DIN 01274099) as Director of the Company
Date of appointment & Terms of appointment	w.e.f.14.08.2025
Brief Profile	Not applicable
Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

**Annexure D****[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with of SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]**

In accordance with the provisions of the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), we hereby inform you that a meeting of the Board of Directors of Jeevan Scientific Technology Limited (the "Company") has approved the recommendation of Nomination and Remuneration Committee (NRC) for granting of 3,00,000 (Three Lakhs Only) Employee Stock Options ("Options") convertible into equal number of Equity Shares of the Company at a face value of Rs. 10/- (Rupees Ten Only) each, to the eligible employees of Company and Subsidiary Company (Nayas Laboratories Private Limited) under the JSTL Employee Stock Option Scheme - 2016 ("Scheme").

The terms of the grant, inter-alia, are as under:

S.No	Particulars	Details
1.	Brief details of options granted	Grant of 3,00,000 (Three Lakhs Only) options to eligible employees. Effective grant date being 14.08.2025.
2.	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Employee Stock Options Scheme 2016 has been formulated and adopted by the Company in terms of the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014.
3.	Total number of shares covered by these options	3,00,000 (Three Lakhs Only) Equity Shares of face value Rs. 10/- (Rupees Ten Only) each. (Each Option is convertible into one Equity Share of the Company).
4.	Pricing Formula	As per the JSTL Employee Stock Option Scheme - 2016 ("Scheme") , the exercise price of the Shares will be decided by NRC.
5.	Options Vested	The said options shall vest as per the policy decided by the NRC but not before 1 year from the date of grant.
6.	Time within which option may be exercised	The exercise period shall be 1 – 5 years from the date of last vesting.



7.	Options exercised	Not applicable
8.	Money realized by exercise of Options	Not Applicable
9.	The total number of Shares arising as a result of exercise of Option	Not Applicable
10.	Options lapsed	Not Applicable
11.	Variation in terms of Options	Not Applicable
12.	Brief details of significant terms	The Scheme is administered by the Nomination and Remuneration Committee. The grant of Options is based upon the eligibility criteria as mentioned in the Scheme. a) The granted Options, once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and applicable taxes in accordance with terms and conditions of the Scheme. b) The granted Options shall vest within minimum period of 1 year and maximum period of 5 years from the date of grant. c) The Exercise Price of the Options granted to an Eligible Employee shall be determined by the Nomination and Remuneration Committee subject to conforming to applicable accounting policies. Provided, however, the Exercise Price shall in no event be less than the face value of the Shares.
13.	Subsequent changes or cancellation or exercise of such Options.	Not Applicable
14.	Diluted earnings per share pursuant to the issue of equity shares on exercise of Options.	Not Applicable

Jeevan Scientific Technology Limited
CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of standalone Unaudited Financial Results for the Quarter ended 30th June 2025

(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

	Particulars	Quarter Ended			Year Ended
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		Unaudited	Audited	Unaudited	Audited
	Revenue from operations				
	(a) Net sales/Income from operations	821.57	892.48	1,251.66	4,360.99
I	Total revenue from operation	821.57	892.48	1,251.66	4,360.99
II	Other Income	37.80	14.10	11.15	62.92
III	Total income (I+II)	859.37	906.58	1,262.81	4,423.90
IV	Expenses				
	(a) Cost of materials consumed	62.27	112.19	94.87	365.10
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	(c) Employee benefits expense	421.47	461.46	365.19	1,565.30
	(d) Finance costs	36.08	35.37	15.45	103.56
	(e) Depreciation and Amortization expense	149.59	152.89	127.84	528.91
	(f) Other Expenses	449.09	409.75	452.53	1,783.97
	Total Expenses (IV)	1,118.50	1,171.66	1,055.88	4,346.86
V	Profit/ (Loss) before Tax (III-IV)	(259.13)	(265.08)	206.93	77.05
VI	Tax Expenses				
	(a) Current tax	-	(41.35)	32.28	12.02
	(b) MAT Credit / (Entitlement)	-	41.35	(32.28)	(12.02)
	(c) Deferred tax	(43.14)	(131.37)	46.85	3.48
	Total tax expense	(43.14)	(131.37)	46.85	3.48
VII	Profit/(Loss) for the period/year (V-VI)	(215.99)	(133.71)	160.08	73.57
VIII	Other Comprehensive Income				
	A (i) Items that will not be reclassified subsequently to profit or loss	-	2.46	-	(1.37)


R. Venkatesh Rao

	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other comprehensive income/(loss) for the period	-	2.46	-	-	(1.37)
IX	Total Comprehensive income for the period (VII+VIII)	(215.99)	(131.25)	160.08	72.20	
X	Paid Up equity share capital (Face value of Rs. 10/- each)	1,583.40	1,583.40	1,548.02	1,583.40	
XI	Other equity			-	3,508.41	
XII	Earnings per equity share (of Rs. 10/- each) (not annualized for the quarters)					
	a) Basic	(1.36)	(0.86)	1.03	0.47	
	b) Diluted	(1.36)	(0.83)	1.03	0.46	

Notes to the Unaudited financial results

- The above Unaudited standalone financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- The above Unaudited standalone results have been reviewed by the Audit Committee at its meeting held on 14th august, 2025 and approved by the Board of Directors of the Company at their meeting held on 14th august, 2025. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and issued unmodified conclusion.
- Employee benefit expenses for the Quarter ending 30th June 2025 includes Rs. 12.02 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
- The company operates in one reportable business segment i.e. Clinical Research Services. Hence segment reporting as per Ind AS 108 is not applicable.
- The results for the Quarter ended 30th June 2025 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited

Place: Hyderabad.
Date: 14th August, 2025

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)



R. Venkateswara Rao
Chief Financial Officer

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30 June 2025

(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Quarter Ended				Year Ended	
	30 June 2025 UnAudited	31 March 2025 Audited	30 June 2024 UnAudited	31 March 2025 Audited		
Revenue from operations						
(a) Net sales/Income from operations	879.91	1,005.79	1,288.03	4,684.36		
Total revenue from operation	879.91	1,005.79	1,288.03	4,684.36		
Other Income	33.43	14.66	11.45	65.26		
II						
Total income (I+II)	913.34	1,020.45	1,299.48	4,749.62		
III						
Expenses						
(a) Cost of materials consumed	77.33	115.38	99.11	380.25		
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade			-	-		
(c) Employee benefits expense	501.76	499.00	398.71	1,705.71		
(d) Finance costs	53.91	54.60	33.20	176.09		
(e) Depreciation and Amortization expense	174.03	177.08	151.39	625.16		
(f) Other Expenses	479.29	429.69	467.64	1,857.34		
Total Expenses (IV)	1,286.32	1,275.75	1,150.05	4,744.55		
V						
Profit/ (Loss) before tax (III-IV)	(372.97)	(255.30)	149.43	5.07		
VI						
Tax expenses						
(a) Current tax	-	(41.35)	32.28	12.02		
(b) MAT Credit / (Entitlement)	-	41.35	(32.28)	(12.02)		
(c) Deferred tax	(51.06)	(129.08)	46.81	(0.84)		
VII						
Profit/(Loss) for the period/year	(321.91)	(126.22)	102.62	5.90		
VIII						
Other Comprehensive Income						
A (i) Items that will not be reclassified subsequently to profit or loss	-	2.46	-	(1.37)		
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-		
B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-		
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-		
IX						
Comprehensive Income for the period /year	-	2.46	-	(1.37)		
Total Comprehensive Income for the period /year	(321.91)	(123.76)	102.62	4.53		



R. Venkateshwar Rao

X	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,583.40	1,583.40	1,548.02	1,583.40
XI	Other equity excluding revaluation reserve	-	-	-	3,410.97
XII	Earnings per Equity share				
	a) Basic (Amount in Rupees)	(2.03)	(0.81)	0.66	0.04
	b) Diluted (Amount in Rupees)	(2.03)	(0.79)	0.66	0.04
XIII	Net profit attributable to:				
	Owners of the company	(310.15)	(129.91)	109.00	13.43
	Non-Controlling interest	(11.76)	3.69	(6.38)	(7.53)
XIV	Other comprehensive income attributable to:				
	Owners of the company	-	2.46	-	(1.37)
	Non-Controlling interest	-	-	-	-
XV	Total comprehensive income attributable to:				
	Owners of the company	(310.15)	(127.45)	109.00	12.06
	Non-Controlling interest	(11.76)	3.69	(6.38)	(7.53)

Notes to the Audited financial results

- 1 The above UnAudited Consolidated financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- 2 The above UnAudited Consolidated results have been reviewed by the Audit Committee at its meeting held on 14th august, 2025 and approved by the Board of Directors of the Company at their meeting held on 14th august, 2025. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and issued unmodified conclusion.
- 3 Employee benefit expenses for the Quarter ending 30th June 2025 includes Rs.12.02 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
- 4 The company operates in one reportable business segment i.e. Clinical Research Services. Hence segmental reporting as per Ind AS 108 is not applicable.
- 5 The results for the Quarter ended 30th June 2025 are also available on website of BSE Limited and on the Company's website.

for Jeewan Scientific Technology Limited

Place: Hyderabad.
Date: 14th August, 2025

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)



R. Venkateswara Rao
Chief Financial Officer




PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pavuluri & Co
Chartered Accountants
FRN : 012194s

CA. N. Rajesh
Partner
M.No : 223169



Place : Hyderabad
Date : 14/08/2025

UDIN # 25223169BMILNU2381



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiary together referred to as "Group"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The consolidated unaudited financial results include the interim financial results of subsidiary company M/s Nayas Laboratories Private Limited. These unaudited financial results and other unaudited financial information have been furnished to us by the management and have been reviewed by us.
5. Based on our review conducted as stated in paragraph 3 above and based on the consideration of the review by us referred in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.






PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

6. We have reviewed the interim financial information of the subsidiary M/s Nayas Laboratories Private Limited included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs 61.35 lakhs for the quarter ended June 30, 2025 total net loss after tax of Rs 105.92 lakhs for the quarter ended June 30, 2025 and total comprehensive loss of Rs 105.92 lakhs for the quarter ended June 30, 2025, as considered in the statement. This interim financial information has been reviewed by us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based on the review done by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

For Pavuluri & Co
Chartered Accountants
FRN : 012194s

CA. N. Rajesh
Partner
M.No : 223169



Place : Hyderabad
Date : 14/08/2025

UDIN # 25223169BMILNV6591

Date: 14-08-2025

To,
The Board of Directors,
Jeevan Scientific Technology Limited
Plot No. 1 & 2, Sai Krupa Enclave Manikonda Jagir,
Near Lanco Hills, Hyderabad, Hyderabad,
Telangana, India, 500008.

Dear Sir/Madam,

Sub: Resignation as Director of the Company

On account of my personal commitments, I am not and will not be in a position to allot the necessary time as a Director of Jeevan Scientific Technology Limited. Hence, I humbly tender my resignation as Non-Executive Director of the Company with immediate effect.

I take this opportunity to thank my colleagues on the Board for their continued support and wish them a great success in all their future endeavors.

Further, I would also like to confirm that there is no other material reason other than the one mentioned above, for my resignation from the Board of the Company.

Thanking you.



~~Yours truly,~~
Thammareddy Ravi